{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:22Z","timestamp":1792785862343,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases","id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23DK125760"],"award-info":[{"award-number":["K23DK125760"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>Risankizumab is approved for adults with Crohn\u2019s disease (CD); pediatric data are limited. We evaluated real-world effectiveness, durability, safety, and dosing in children with CD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective, global multicenter cohort of patients &amp;lt;18\u2009years initiating risankizumab monotherapy (2022-2025). The outcomes were primary: corticosteroid-free clinical remission (CFR, wPCDAI &amp;lt; 12.5) post-induction (Week 12) among those with clinically active (wPCDAI \u2265 12.5) disease at start; secondary: clinical response (decrease wPCDAI \u2265 17.5-points), C-reactive protein (CRP) remission (&amp;lt;5\u2009mg\/L), CFR\u2009+\u2009CRP remission, intestinal ultrasound (IUS) remission, CFR at Weeks 30\/54, therapy durability, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 96 (median age 15 [IQR: 13-16] years; 51% male; 70% ileocolonic; 38% prior ustekinumab) started on risankizumab, 68 (71%) had active disease at start. Nearly all (93\/96, 97%) received the adult induction regimen\u20143\u2009&amp;lt;\u200930\u2009kg received a median 383\u2009mg\/m\u00b2 (IQR: 339-397). Post-induction CFR was achieved in 28\/68 (41%), clinical response in 37\/68 (54%), and combined CFR\u2009+\u2009CRP in 22\/68 (32%). Week 30 and 54 CFR were attained in 34\/68 (50%) and 34\/68 (50%), respectively. In the full cohort, median follow-up was 53.5\u2009weeks (IQR: 47-60); 86\/96 (90%) remained on risankizumab. Durability was greater with post-induction CFR (log-rank P\u2009=\u2009.008; Cox HR 0.21, 95% CI 0.06-0.75; P\u2009=\u2009.02). Lower baseline ESR predicted higher odds of post-induction CFR (OR 0.97 per mm\/h; 95% CI 0.94-0.99; P\u2009=\u2009.01). No serious safety events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this multicenter pediatric cohort, risankizumab induced meaningful clinical and biomarker improvement with durable remission and a favorable safety profile, supporting risankizumab as an effective option for children with CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag134","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:27:44Z","timestamp":1787570864000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of risankizumab induction and maintenance therapy in pediatric patients with Crohn\u2019s disease: a multicenter retrospective analysis"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-1164","authenticated-orcid":false,"given":"Elizabeth A","family":"Spencer","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Mount Sinai Hospital , New York City, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Buck","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Harvard Medical School and Boston Children\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7769-8123","authenticated-orcid":false,"given":"Lauren V","family":"Collen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Harvard Medical School and Boston Children\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Stein","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, The Children\u2019s Hospital of Philadelphia , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Babinski","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, The Children\u2019s Hospital of Philadelphia , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror S","family":"Shouval","sequence":"additional","affiliation":[{"name":"The Institute of Pediatric Gastroenterology, Hepatology and Nutrition, Schneider Children\u2019s Hospital , Petach-Tikva,","place":["Israel"]},{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7634-5310","authenticated-orcid":false,"given":"Firas","family":"Rinawi","sequence":"additional","affiliation":[{"name":"The Pediatric Gastroenterology Unit, Afula HaEmek Medical Center , Afula,","place":["Israel"]},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion , Haifa,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7398-4926","authenticated-orcid":false,"given":"Richard K","family":"Russell","sequence":"additional","affiliation":[{"name":"The Paediatric Gastroenterology Department, Royal Hospital for Children and Young People , Edinburgh,","place":["Scotland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Zifman","sequence":"additional","affiliation":[{"name":"Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv,","place":["Israel"]},{"name":"The Pediatric Gastroenterology Unit, Meir Medical Center , Kfar-Saba,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chani","family":"Topf-Olivestone","sequence":"additional","affiliation":[{"name":"Assuta Ashdod University Hospital Department of Pediatrics, , Ashdod,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Tzvinikos","sequence":"additional","affiliation":[{"name":"Al Jalila Children\u2019s Specialty Hospital, Mohamed Bin Rashid University of Medicine and Health Sciences Gastroenterology Department, , Dubai,","place":["United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Slae","sequence":"additional","affiliation":[{"name":"The Pediatric Gastroenterology Unit, Hadassah Medical Center , Jerusalem,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Lev-Tzion","sequence":"additional","affiliation":[{"name":"The Juliet Keidan institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The\u00a0Hebrew University , Jerusalem,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Turner","sequence":"additional","affiliation":[{"name":"The Juliet Keidan institute of Pediatric Gastroenterology and Nutrition, The Eisenberg R&D Authority, Shaare Zedek Medical Center, The\u00a0Hebrew University , Jerusalem,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla C","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Nutrition, Mount Sinai Hospital , New York City, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2787-4096","authenticated-orcid":false,"given":"Amit","family":"Assa","sequence":"additional","affiliation":[{"name":"The Pediatric Gastroenterology Unit, Kaplan Medical Center, Rehovot and the Hebrew University , Jerusalem,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2026093013240167100_jjag134-B1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","article-title":"Approach to the management of recently diagnosed inflammatory bowel disease patients: a user\u2019s guide for adult and pediatric gastroenterologists","volume":"161","author":"Agrawal","year":"2021","journal-title":"Gastroenterology"},{"key":"2026093013240167100_jjag134-B2","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-058037","article-title":"Pediatric inflammatory bowel disease","volume":"151","author":"Bouhuys","year":"2023","journal-title":"Pediatrics"},{"key":"2026093013240167100_jjag134-B3","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026093013240167100_jjag134-B4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/ibd\/izy313","article-title":"A practical guide to the safety and monitoring of new IBD therapies","volume":"25","author":"Click","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026093013240167100_jjag134-B5","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"2026093013240167100_jjag134-B6","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 advance and motivate induction trials","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"2026093013240167100_jjag134-B7","doi-asserted-by":"crossref","first-page":"S-16","DOI":"10.1016\/S0016-5085(25)01002-9","article-title":"Ustekinumab open-label induction and randomized blinded maintenance therapy in pediatric participants with moderately to severely active Crohn\u2019s disease: the phase 3 UNITI jr study","volume":"169","author":"Greef","year":"2025","journal-title":"Gastroenterology"},{"key":"2026093013240167100_jjag134-B8","author":"European Medicines Agency"},{"key":"2026093013240167100_jjag134-B9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"key":"2026093013240167100_jjag134-B10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/apt.17358","article-title":"Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn\u2019s disease: a GETAID multicentre cohort study","volume":"57","author":"Fumery","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093013240167100_jjag134-B11","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf070","article-title":"A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn\u2019s disease","volume":"19","author":"Johnson","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026093013240167100_jjag134-B12","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026093013240167100_jjag134-B13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ibd.21649","article-title":"Mathematical weighting of the pediatric Crohn\u2019s disease activity index (PCDAI) and comparison with its other short versions","volume":"18","author":"Turner","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2026093013240167100_jjag134-B14","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/ibd\/izad315","article-title":"Real-world effectiveness and safety of risankizumab in patients with moderate to severe multirefractory Crohn\u2019s disease: a Belgian multicentric cohort study","volume":"30","author":"Alsoud","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026093013240167100_jjag134-B15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jpn3.70163","article-title":"Long-term effects of ustekinumab in children with inflammatory bowel disease: a systematic review","volume":"81","author":"Marques","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026093013240167100_jjag134-B16","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.14309\/ajg.0000000000002679","article-title":"Biological agents in the treatment of Crohn\u2019s disease: a propensity score-matched analysis from the prospective persistence Australian national IBD cohort (panic3) study","volume":"119","author":"Chetwood","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026093013240167100_jjag134-B17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026093013240167100_jjag134-B18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.cgh.2024.09.039","article-title":"Outcomes after dose intensification of risankizumab for Crohn\u2019s disease","volume":"23","author":"Dalal","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026093013240167100_jjag134-B19","doi-asserted-by":"crossref","first-page":"644003","DOI":"10.3389\/fmed.2021.644003","article-title":"Running behind \u201cpopo\u201d-impact of predictors of poor outcome for treatment stratification in pediatric Crohn\u2019s disease","volume":"8","author":"de Laffolie","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026093013240167100_jjag134-B20","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1093\/ibd\/izad275","article-title":"Clusters of disease activity and early risk factors of clinical course of pediatric Crohn\u2019s disease","volume":"30","author":"Distante","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026093013240167100_jjag134-B21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/MPG.0000000000003374","article-title":"Long-term follow-up and predictors of complicated disease behavior in pediatric Crohn\u2019s disease patients","volume":"74","author":"Kori","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026093013240167100_jjag134-B22","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf075","article-title":"Early intestinal ultrasound response to biologic and small molecule therapy is accurate to predict treat-to-target endoscopic outcomes in children with ulcerative colitis: results from the prospective super sonic-uc study","volume":"19","author":"Dolinger","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026093013240167100_jjag134-B23","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ecco-jcc\/jjac072","article-title":"Intestinal ultrasound early on in treatment follow-up predicts endoscopic response to anti-TNF\u0391 treatment in Crohn\u2019s disease","volume":"16","author":"de Voogd","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026093013240167100_jjag134-B24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jpn3.70049","article-title":"Defining normal bowel wall thickness in children with inflammatory bowel disease in deep remission: a multicenter study on behalf of the pediatric committee of the International Bowel Ultrasound Group (IBUS)","volume":"81","author":"Kellar","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/9\/jjag134\/71527121\/jjag134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/9\/jjag134\/71527121\/jjag134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:24:11Z","timestamp":1790789051000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag134\/8854572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag134","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9]]},"article-number":"jjag134"}}